Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

This study is looking for 52 adults, aged 18-65, who have obesity (BMI 30-45) and high blood pressure (pre-hypertension or hypertension). The purpose is to see if the investigational drug, Angiotensin-(1-7), can improve heart and blood vessel health. You will receive either Angiotensin-(1-7) or a saline placebo through an IV. Researchers will measure changes in nerve activity to your muscles and the size of your arm artery to see if the treatment is successful. The study is currently recruiting participants.

Study design: This is a randomized, double-blind, placebo-controlled crossover study involving 52 participants.
What's involved: You will have a screening visit and, if eligible, two study visits, each lasting about 4 hours. During these visits, you will receive an IV infusion for approximately two hours.
Compensation: Not stated in the trial record.
Follow-up: Measurements will be taken at 120 minutes during the study visits.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Recruiting

EARLY_PHASE1Ages 18–65InterventionalBasic science

Milton S. Hershey Medical Center

~52 participants

Updated 2025-09-19 on ClinicalTrials.gov

What's tested:Angiotensin-(1-7)Saline

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change in Muscle Sympathetic Nerve Burst Rate

Measured over 120 minutes

+1 more outcome measured

Conditions

Obesity

Hypertension

Where it's being run

1 sites across 1 states

Pennsylvania1

Study leadership

Amy Arnold, PhD · PRINCIPAL_INVESTIGATOR · Pennsylvania State University College of Medicine

Who to contact

Aimee Cauffman, RN

[email protected]

717-531-1617

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Men and women of all races

Age 18 to 65 years

Body mass index (BMI) between 30-45 kg/m2

Pre-hypertension (defined as two or more seated blood pressure readings \>120/80 mmHg) or hypertension (defined as two or more seated blood pressure readings \>130/80 mmHg or use of antihypertensive medications)

Capable of giving informed consent

Fluent in written and spoken English

Satisfactory history and physical exam

Exclusion

Age ≤ 17 or ≥ 66 years

Taking more than two antihypertensive medications

Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease)

Pregnant or nursing women

Women taking hormone replacement therapy within 6 months

Decisional impairment

Prisoners

Alcohol or drug abuse

Current smokers

Highly trained athletes

Subjects with \>5% weight change in the past 3 months

BMI \> 45 kg/m2

Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)

History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack)

History or presence of immunological or hematological disorders

Impaired hepatic function \[aspartate aminotransferase (AST) or alanine transaminase (ALT) levels \>2 times upper limit of normal range\]

Impaired renal function (serum creatinine \>2.0 mg/dl)

Anemia

Treatment with drugs increasing sympathetic activity \[e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors, stimulants\]

Treatment with phosphodiesterase-5 inhibitors

Treatment with anticoagulants (e.g. warfarin)

Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month)

Treatment with any investigational drug in the 1-month preceding the study

Inability to give, or withdraw, informed consent

What this trial measures

Change in Muscle Sympathetic Nerve Burst Rate120 minutes
Muscle sympathetic nerve burst rate will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.
Change in Brachial Artery Diameter120 minutes
A blood pressure cuff will be inflated to a suprasystolic pressure for 5 minutes then deflated. Brachial artery diameter will be measured continuously before, during, and after cuff inflation using duplex ultrasound at baseline and at the end of angiotensin-(1-7) versus saline infusion.

Trialytics